University of Minnesota
https://twin-cities.umn.edu/
612-625-5000

June to July 2025

Preclinical evaluation of sequential vaccination with a conserved HA stalk-focused vaccine (group 2 chimeric HA inactivated split vaccine) and an adjuvanted recombinant NA protein (rNA-N2-MPP), reported in Puente-Massaguer 2025

Results of a phase 1b randomized, double-blind, placebo-controlled trial of the safety, reactogenicity, and immunogenicity of FluGen’s intranasal M2SR H3N2 next-generation influenza vaccine in children, posted in NCT04960397

Preclinical evaluation of broadly protective immune responses elicited by computationally optimized broadly-reactive H1 and H3 antigens expressed from a self-amplifying mRNA vector platform (samRNA-COBRA), reported in Pierce 2025

Moderna reported safety and immunogenicity results from a phase 1/2 trial (NCT05333289) of mRNA-based next-generation influenza vaccine candidates (mRNA-1020 and mRNA-1030) encoding HA and NA antigens at different HA:NA ratios in Rudman Spergel 2025.

Relative vaccine efficacy against influenza illness elicited by Moderna’s mRNA-1010 next-generation candidate, compared with licensed seasonal influenza vaccine, in a randomized controlled phase 3 trial (NCT06602024) in 40,805 adults aged 50 and older in 11 countries, reported in a 6/30/25 press release; Moderna plans to publish the data in a peer-reviewed journal and submit an application for regulatory approval.

Preliminary safety, immunogenicity, and reactogenicity data from a phase 3 trial of Novavax’s combination COVID+influenza nanoparticle vaccine candidate (CIC) and next-generation influenza vaccine candidate (Nano-Flu, tNIV) in adults aged 65 and older, reported in a 6/11/25 press release

Preclinical evaluation of mucosal and systemic humoral and cellular immune responses induced by intranasal administration of an adjuvanted recombinant NA-based influenza vaccine candidate, rNA-N1-MPP, reported in Vasilev 2025

Preclinical evaluation of broadly protective immune responses induced by mucosal immunization with conserved NP antigens from influenza A and B viruses linked to the autophagy-inducing peptide C5 based on a bovine adenoviral vector, reported in Wang 2025

May to June 2025

Reactogenicity, safety, and immunogenicity of Osivax’s NP-based OVX836 vaccine candidate co-administered with a licensed seasonal influenza vaccine in a Phase 2a trial NCT05284799, published in Groth 2025

Preclinical evaluation of intranasal delivery of a multi-subtype consensus NA-M2e VLP vaccine candidate, reported in Raha 2025

Development of recombinant H3 COBRA HA antigens using A(H3N2) HA sequences circulating from 2018-2022 to elicit broadly protective antibodies against A(H3N2) strains in animal models, reported in Allen 2025

Results of a Phase 3 trial NCT06097273 of Moderna’s mRNA-1083 combination COVID+influenza vaccine candidate, published in Rudman Spergel 2025

Preclinical evaluation of a centralized consensus NA immunogen delivered via an adenovirus vector, reported in Pekarek 2025

Results of a Phase 1/2 trial NCT05052697 of Pfizer’s next-generation quadrivalent mRNA vaccine candidate, qIRV, reported in Branche 2025

April to May 2025

EU-funded public-private partnership formed to develop Vivaldi's DeltaFLU vaccine candidate, announced in Cnossen 2025

US HHS funding announced to develop NIAID's BPL-1357, as noted in STAT and KFF Health News. Results of NIAID's BPL-1357 Phase 1 trial NCT05027932 posted on Clinicaltrials.gov

Analysis of broadly protective immune responses in newborn NHPs to NIAID’s HA-stem ferritin nanoparticle vaccine (H1ssF+AddaVax) in Crofts 2025

Results of Moderna's mRNA-1010 Phase 3 trials NCT05415462 and NCT05566639 published in Kandinov 2025

Analysis of B cell responses against broadly protective epitopes of the HA stalk domain following chimeric HA vaccination, published in Guthmiller 2025

New Phase 1 trial NCT06863142 of NIAID’s FluMos-v2 mosaic hexavalent nanoparticle vaccine with and without ALFQ adjuvant